Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898923 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
A Phase 3 study, sponsored by Oneness Biotech Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
NCT01898923 is a Phase 3 study that has completed, run by Oneness Biotech Co.. The registered enrollment target is 236 participants.
The verdict
NCT01898923, a Phase 3 study, has completed, sponsored by Oneness Biotech Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events and clinical laboratory abnormalities.
Interventions
- DRUG ON101 Cream
- OTHER Aquacel® Hydrofiber® dressing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2012-11-23 |
| Est. Completion | 2020-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898923
The ClinicalTrials.gov registry entry for NCT01898923 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oneness Biotech Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ON101 Cream is the first listed.
NCT01898923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01898923 about?
NCT01898923 is a clinical study titled "Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers". The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events ...
What is the current status of trial NCT01898923?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2012-11-23. Estimated completion is 2020-05-11.
What interventions are being tested in trial NCT01898923?
The interventions under investigation include: ON101 Cream (DRUG), Aquacel® Hydrofiber® dressing (OTHER).
Who is sponsoring clinical trial NCT01898923?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.